Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

<p>Genomic landscape in patient-derived preclinical models. The genetic alteration of the PDC (patient-derived cell), PDO (patient-derived organoid), and PDX (patient-derived xenograft) models are shown as an oncoprint plot.</p>

Gardado en:
Detalles Bibliográficos
Autor Principal: Seung Yeon Oh (15051017) (author)
Outros autores: You Won Lee (15051020) (author), Eun Ji Lee (15051023) (author), Jae Hwan Kim (15051026) (author), YoungJoon Park (15051029) (author), Seong Gu Heo (15032490) (author), Mi Ra Yu (15051032) (author), Min Hee Hong (15014541) (author), John DaSilva (15051035) (author), Christopher Daly (15030374) (author), Byoung Chul Cho (15032496) (author), Sun Min Lim (15051038) (author), Mi Ran Yun (15032484) (author)
Publicado: 2025
Subjects:
Cancer
Therapeutic Research and Development
Drug Resistance
Clinical drug resistance
Lung Cancer
Translational Research
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
Sexa o primeiro en deixar un comentario!
You must be logged in first

Títulos similares